Full-Time

Head-Market Access

Posted on 3/13/2025

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

No salary listed

Senior, Expert

Mumbai, Maharashtra, India

Travelling requirement: Ability to travel 40% of the times, including ability to travel within country.

Category
Strategy Development
Business Development
Business & Strategy
Required Skills
Market Research
Requirements
  • Bachelor's degree in Life Sciences, Business, Health Economics, or a related field
  • Minimum 15 years of experience in market access, health economics, or a related field
  • 3-4 years of people leadership experience is required
  • Demonstrated market access experience across critical or rare disease therapy area and vaccines is highly desirable
  • Proven track record in developing and implementing successful market access strategies
  • Ability to work in complex evolving health landscape and work with CFT / lead team
Responsibilities
  • Develops market access strategy for existing and upcoming therapies of Takeda in India LOC while strengthening the policies around reimbursement and access
  • Analyzes the potential of new Takeda assets (Wave I therapies) in alignment with Medical and Business operations team and represents India LOC to Area & Regional team to align on future launch strategies
  • Collaborates with Business unit, Medical and Business Operations team to build the Business Plan of upcoming therapies and leads the business planning strategies from Public Market segment
  • Collaborates with Area & Regional team to develop and strategies innovative access models to help accelerate access of new & existing therapies in public & private market segment
  • Shares key market insights from public segment to Business unit, PAPA and Medical Team to stay agile on existing execution plan for timely incorporation of any changes, as required
  • Be the expert in public procurement strategies and lead the prioritization of business unit Goals from public market segment
  • Lead the development of pre-launch market research from Public Market Segment and exploration of access pathways for Out-of-Pocket market in collaboration with CFT
  • Collaborate with business units to set the MRP (Mid-Range Plan) and LRF (Long Range Forecast) plans and Brand Planning initiative from Public Market perspective as well as innovative access planning in Private Market
  • Provide Leadership and develop team to become the experts and lead the execution of tactical plan for respective business units
  • Work on development of Market Access Managers to build access priorities with tangible KPI’s to monitor progress on key project milestones
  • Build a coaching culture in the team to help the team members define clear business unit priorities and strategize execution planning to focus on key deliverables and lead cross functional collaboration
  • Lead the development and execution of innovative access tools like HEOR, Budget Impact Model, Innovative Access Model with demonstrated outcome to support business unit priorities
Desired Qualifications
  • A master’s degree or MBA is preferred
  • Demonstrated market access experience across critical or rare disease therapy area and vaccines is highly desirable

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and commercialize them, with a goal of launching up to 15 new products by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to provide life-changing therapies while ensuring that patient needs are prioritized and environmental risks are managed.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...